感染性休克伴呼吸衰竭患者的亚低温治疗(CASS):一项随机、对照、开放标签试验。

Induced hypothermia in patients with septic shock and respiratory failure (CASS): a randomised, controlled, open-label trial.

机构信息

Department of Anesthesia and Intensive Care, Nordsjællands Hospital, Hillerød, Denmark; Centre of Excellence in Immunity and Infection/Centre of Excellence for Personalised Medicine of Infectious Complications in Immune Deficiency, Department of Infectious Diseases, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.

Centre of Excellence in Immunity and Infection/Centre of Excellence for Personalised Medicine of Infectious Complications in Immune Deficiency, Department of Infectious Diseases, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.

出版信息

Lancet Respir Med. 2018 Mar;6(3):183-192. doi: 10.1016/S2213-2600(18)30004-3. Epub 2018 Jan 8.

Abstract

BACKGROUND

Animal models of serious infection suggest that 24 h of induced hypothermia improves circulatory and respiratory function and reduces mortality. We tested the hypothesis that a reduction of core temperature to 32-34°C attenuates organ dysfunction and reduces mortality in ventilator-dependent patients with septic shock.

METHODS

In this randomised, controlled, open-label trial, we recruited patients from ten intensive care units (ICUs) in three countries in Europe and North America. Inclusion criteria for patients with severe sepsis or septic shock were a mean arterial pressure of less than 70 mm Hg, mechanical ventilation in an ICU, age at least 50 years, predicted length of stay in the ICU at least 24 h, and recruitment into the study within 6 h of fulfilling inclusion criteria. Exclusion criteria were uncontrolled bleeding, clinically important bleeding disorder, recent open surgery, pregnancy or breastfeeding, or involuntary psychiatric admission. We randomly allocated patients 1:1 (with variable block sizes ranging from four to eight; stratified by predictors of mortality, age, Acute Physiology and Chronic Health Evaluation II score, and study site) to routine thermal management or 24 h of induced hypothermia (target 32-34°C) followed by 48 h of normothermia (36-38°C). The primary endpoint was 30 day all-cause mortality in the modified intention-to-treat population (all randomly allocated patients except those for whom consent was withdrawn or who were discovered to meet an exclusion criterion after randomisation but before receiving the trial intervention). Patients and health-care professionals giving the intervention were not masked to treatment allocation, but assessors of the primary outcome were. This trial is registered with ClinicalTrials.gov, number NCT01455116.

FINDINGS

Between Nov 1, 2011, and Nov 4, 2016, we screened 5695 patients. After recruitment of 436 of the planned 560 participants, the trial was terminated for futility (220 [50%] randomly allocated to hypothermia and 216 [50%] to routine thermal management). In the hypothermia group, 96 (44·2%) of 217 died within 30 days versus 77 (35·8%) of 215 in the routine thermal management group (difference 8·4% [95% CI -0·8 to 17·6]; relative risk 1·2 [1·0-1·6]; p=0·07]).

INTERPRETATION

Among patients with septic shock and ventilator-dependent respiratory failure, induced hypothermia does not reduce mortality. Induced hypothermia should not be used in patients with septic shock.

FUNDING

Trygfonden, Lundbeckfonden, and the Danish National Research Foundation.

摘要

背景

严重感染的动物模型表明,诱导性低温持续 24 小时可改善循环和呼吸功能,降低死亡率。我们检验了这样一种假设,即核心体温降至 32-34°C 可减轻器官功能障碍并降低败血症性休克伴呼吸机依赖患者的死亡率。

方法

这是一项在欧洲和北美三个国家的十个重症监护病房(ICU)进行的随机、对照、开放性临床试验。严重败血症或败血症性休克患者的纳入标准为平均动脉压<70mmHg、在 ICU 中接受机械通气、年龄至少 50 岁、预计 ICU 入住时间至少 24 小时、并在符合纳入标准后 6 小时内入组研究。排除标准为不受控制的出血、有临床意义的出血性疾病、近期开放性手术、妊娠或哺乳、或非自愿性精神科住院。我们将患者以 1:1 的比例随机分配(采用可变大小的区块,范围从 4 到 8;按死亡率预测因素、年龄、急性生理学和慢性健康评估 II 评分和研究地点分层)至常规体温管理或 24 小时诱导性低温(目标 32-34°C),随后进行 48 小时的正常体温(36-38°C)。主要终点为改良意向治疗人群(除因撤回同意或在随机分组后但在接受试验干预前发现符合排除标准而被排除的所有随机分配患者)的 30 天全因死亡率。干预措施的给予者和医疗保健专业人员未对治疗分配进行盲法,但主要结局评估者除外。该试验在 ClinicalTrials.gov 注册,编号为 NCT01455116。

结果

在 2011 年 11 月 1 日至 2016 年 11 月 4 日期间,我们筛选了 5695 名患者。在计划招募的 560 名患者中的 436 名入组后,由于无效性(220[50%]随机分配至低温组和 216[50%]至常规体温管理组),试验提前终止。在低温组中,217 名患者中有 96(44.2%)在 30 天内死亡,而常规体温管理组中 215 名患者中有 77(35.8%)死亡(差异 8.4%[95%CI-0.8 至 17.6];相对风险 1.2[1.0-1.6];p=0.07)。

结论

在败血症性休克和呼吸机依赖性呼吸衰竭患者中,诱导性低温并不能降低死亡率。败血症性休克患者不应使用诱导性低温。

资金

Trygfonden、Lundbeckfonden 和丹麦国家研究基金会。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索